LianBio (LIAN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LIAN Stock Price Chart Interactive Chart >
LIAN Price/Volume Stats
| Current price | $2.49 | 52-week high | $6.24 |
| Prev. close | $2.40 | 52-week low | $1.07 |
| Day low | $2.43 | Volume | 48,032 |
| Day high | $2.58 | Avg. volume | 313,897 |
| 50-day MA | $1.87 | Dividend yield | N/A |
| 200-day MA | $2.32 | Market Cap | 269.80M |
LianBio (LIAN) Company Bio
Lianbio operates in the healthcare industry focusing on pharmaceutical business. The company is based in Camana Bay, Cayman Islands.
Latest LIAN News From Around the Web
Below are the latest news stories about LIANBIO that investors may wish to consider to help them evaluate LIAN as an investment opportunity.
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in ChinaAs a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments. |
Pfizer Opts In To LianBio Rights to Respiratory Syncytial Virus Candidate In Greater ChinaPfizer Inc (NYSE: PFE) has opted into the right to develop and commercialize LianBio's (NASDAQ: LIAN) sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in Mainland China, Hong Kong, Macau, and Singapore under the companies' existing strategic collaboration to expand patient access in Greater China. In June 2022, Pfizer acquired ReViral Ltd. and its portfolio of RSV therapeutic candidates, except development and commercialization rights for sisunatovir in Mainland China, Hon |
Pfizer gains rights to experimental RSV treatment in China, Hong Kong, Macau and SingaporePfizer Inc. said Monday that it will help develop and commercialize sisunatovir, LianBio's experimental respiratory syncytial virus (RSV) treatment candidate, in mainland China, Hong Kong, Macau and Singapore. Sisunatovir is being tested as a treatment for pediatric and adult patients. The agreement follows Pfizer's acquisition earlier this year of ReViral Ltd., which had licensed development and commercialization rights to sisunatovir to LianBio in the four regions. Pfizer will pay LianBio $20 |
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and SingaporePfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive a $20 million upfront payment, to be released from previously restricted cash paid by Pfizer to LianBio in 2020 under the companies’ existing strategic collaborationLianBio is eligible to receive up to $135 million in potential development and commercial milestone payments and tiered low single digit percent of net sales in the territories SHANGHAI, China |
LianBio Announces President and Chief Strategy Officer DepartureSHANGHAI, China and PRINCETON, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Debra Yu, M.D., LianBio’s President and Chief Strategy Officer, has resigned from the Company, effective January 1, 2023, to pursue other business and professional interests and opportunities. To facilitate her transition, Dr. Yu entered into a consulting agreement |
LIAN Price Returns
| 1-mo | 51.83% |
| 3-mo | 74.13% |
| 6-mo | 9.21% |
| 1-year | -36.15% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 51.83% |
| 2022 | -73.38% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...